Increased use of earnouts is likely to facilitate M&A deals across sectors in Europe.
Earnouts are increasingly common in European M&A. The growing prevalence of this contractual provision — in which additional...more
5/18/2023
/ Acquisitions ,
Business Valuations ,
Contract Terms ,
De-Risking ,
Early Stage Companies ,
Earn-Outs ,
EBITDA ,
Energy Sector ,
EU ,
Life Sciences ,
Mergers ,
Technology Sector ,
Valuation
What types of transactions are classifed as ‘corporate reorganisations’ in your jurisdiction?
The term ‘corporate reorganisation’ can be used to mean a wide variety of transactions, but is most typically used to refer to...more
Welcome to the first edition of our European Healthcare & Life Sciences Market Update, a new report summarising key emerging trends, opportunities, and challenges facing the market in 2022. During the last 12 months, the...more
2/10/2022
/ Clinical Trials ,
Digital Health ,
EU ,
EU Clinical Trials Regulation (CTR) ,
Health Care Providers ,
Joint Venture ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Regulatory Standards ,
UK ,
Venture Capital
Proposed changes to the UK Listing Rules would allow certain SPACs to avoid a listing suspension.
Key Points:
..The FCA is proposing to amend its rules so that SPACs meeting certain conditions and disclosure...more
What types of transactions are classified as ‘corporate reorganisations’ in your jurisdiction?
The term ‘corporate reorganisation’ can be used to mean a wide variety of transactions, but is most typically used to refer to...more
If 2020 was the year that COVID-19 precipitated extraordinary government intervention and regulation of our lives, 2021 looks set to be the year that regulatory interventions in M&A precipitate changes to the way that...more
As the healthcare and technology sectors converge to create revolutionary new products and innovations, companies operating in very distinct regulatory and business environments must find ways to adapt and cooperate. When...more
Emerging companies have historically been backed by venture capital funds, but as Europe’s startup scene matures, involvement by more traditional private equity investors is growing, particularly in the tech, consumer, and...more
12/17/2020
/ Buyouts ,
Digital Health ,
Emerging Growth Companies ,
Emerging Technology Companies ,
Investors ,
Life Sciences ,
Private Equity ,
Private Equity Firms ,
Startups ,
Target Company ,
Technology Sector
As private equity targets emerging companies, PE investors are expanding VC deal terms and dynamics.
Emerging companies have historically been backed by venture capital funds, but as Europe’s startup scene matures,...more
Buyout firms planning an acquisition or preparing a portfolio company for exit must consider the impact of poor corporate culture, particularly on a potential IPO.
No institution, whatever its geography, industry, sector,...more
It is now apparent that no institution or business unit, whatever its geography, industry, sector, or size, is above the negative impact of a poor culture. Culture-related issues at Uber, Sports Direct, Boeing, and others...more
The scheme opens on 20 May 2020 and is available on a “first come, first served” basis.
On 18 May 2020, the UK government released a draft of its convertible loan note agreement and details of the application process for...more
The UK government is pledging at least £250 million in convertible loan notes to UK-registered businesses.
On 20 April 2020, the UK government issued a press release announcing a new Future Fund scheme for the financing of...more
In a complex and competitive market, minimising and mitigating risk in M&A is a key concern for deal teams. High demand for assets saw strong deal volumes and values in 2019, following a standout year in 2018. The search for...more
‘Corporate reorganisation’ is something of an umbrella term, and is used in many different contexts to mean a multitude of different things. At one extreme, a reorganisation may refer to ‘paper’ changes to a corporate group’s...more
6/5/2019
/ Corporate Restructuring ,
Corporate Taxes ,
Debt Restructuring ,
EU ,
EU Passport ,
Financial Accounting ,
Insolvency ,
Internal Controls ,
Jurisdiction ,
Regulatory Standards ,
Shareholder Approval ,
UK ,
UK Brexit
Companies should act now to prepare for the full implementation of the MDR and IVDR.
On 26 May 2020, Regulation (EU) 2017/745 on medical devices (MDR) will become fully active, reflecting an overhaul of the current...more
Corporates should leverage growing carve-out and divestment activity across the European market with a strategic approach to deal making.
In the current deal market, corporates are taking an increasingly strategic and...more
The guidance provides helpful clarity on key regulatory changes impacting life sciences companies in the event of a no-deal Brexit.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a...more
4/4/2019
/ Article 50 Treaty of the EU ,
EU ,
European Economic Area (EEA) ,
Health Care Providers ,
Healthcare ,
Life Sciences ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
New Guidance ,
New Legislation ,
No-Deal Brexit ,
Pharmaceutical Industry ,
Time Extensions ,
UK ,
UK Brexit ,
Withdrawal Agreement
Latham partner Robbie McLaren explains the term 8+2+1 from the Book of Jargon® – Healthcare & Life Sciences.
The Book of Jargon® – Healthcare & Life Sciences is one of a series of practice area and industry-specific...more
11/17/2017
How to thrive amid uncertainty? This was the question we explored at the 35th FT Global Pharmaceutical and Biotechnology Conference. Here are five key industry trends and corresponding practical legal tips to help companies...more
Britain’s decision to leave the European Union in June 2016, coupled with the election of Donald Trump as US president in November 2016, gave dealmakers plenty of pause for thought last year – but ultimately did little to...more